GeneDx Holdings Corporation (WGS) ニュース

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx...

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx...

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical...

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77...

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the...

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

Data to be presented at the International Conference on Newborn Sequencing (ICoNS) highlighting lessons learned from the GUARDIAN and Early Check...

GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results...

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of September...

Form 144 - Report of proposed sale of securities

GeneDx to Participate in Fall Investor Conferences

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will...

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights

Reported second quarter 2024 revenue from continuing operations1 of $68.9M with 77% year-over-year growth of exome and genome test revenue...